Form 4: Amgen VP Matthew Busch Reports Stock Disposition

Amgen Inc. VP of Finance and CAO Matthew C. Busch reported the disposition of 68 shares of common stock to cover tax obligations.

Summary

• Matthew C. Busch, VP of Finance and CAO at Amgen Inc., disposed of 68 shares of common stock on May 2, 2026.
• The shares were disposed of in two transactions of 30 and 38 shares respectively, both at a price of $329.82 per share.
• The transactions were executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following these transactions, the reporting person maintains beneficial ownership of 3,980 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a market-driven investment decision.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• None identified; this is a standard regulatory filing for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this document.

Industry Context

StockSavvy.ai notes that routine Form 4 filings involving tax withholding upon the vesting of equity awards are standard practice for corporate executives and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices in the biotechnology sector where equity-based incentives are common.
• The use of 'sell-to-cover' transactions is a standard industry mechanism for managing tax liabilities associated with restricted stock unit vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related adjustment.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Executive Compensation, SEC Filing